Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2017

View Archived Issues

XyloCor Therapeutics' XC-001 awarded FDA fast track designation

Rasna Therapeutics provides update on RASP-101

FDA approves Kisqali Femara Co-Pack

resTORbio initiates phase IIb study of RTB-101 to reduce respiratory tract infections in the elderly

Pfizer reviews key developments of first quarter 2017

PaxVax initiates clinical trial program for modernized Ad 4/7 vaccine

FDA authorizes IND application for NANT cancer vaccine clinical trials

RET kinase inhibitor GSK-589 shows promise for IBS treatment

Auris Medical reports results from extension study of AM-101 for tinnitus

STRATOS 1 trial of tralokinumab in severe asthma does not meet primary endpoint

Corvus Pharmaceuticals enters immuno-oncology agreement with Monash University

Apellis Pharmaceuticals granted E.U. orphan drug designation for APL-2 in PNH

FDA approves Bavencio for advanced urothelial carcinoma

Array reports part 2 data from COLUMBUS study of binimetinib and encorafenib in advanced melanoma

Pharnext and Tasly enter strategic agreement

Recro Pharma reports positive topline data from phase III study of intravenous meloxicam

FDA grants orphan drug designation to XmAB-5871

FORUM Pharmaceuticals discovers novel nicotinic alpha7 receptor agonists

TXP Pharma identifies new N-formyl peptide receptor 2 agonists

Novel compounds for parasitic protozoal infections discovered at GlaxoSmithKline

Selvita divulges new MKNK1/MKNK2 inhibitors

Merck & Co. describes novel antituberculosis compounds

Redx Pharma presents data for REDX-08106 as a potent antibacterial compound

IMvigor211 study of Tecentriq in advanced bladder cancer does not meet primary endpoint

Universite de Montreal discloses novel proteinase-activated receptor 4 antagonists

CD26, a marker of hepatic inflammation in hepatitis E virus infection

Clinical benefit seen with upadacitinib tartrate in Crohn's disease patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...